Overview

The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
We aim to assess the the efficiency and safety of N-acetylcysteine for prevention of thrombotic events after allogenic hematopoietic stem cell transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
Acetylcysteine
Busulfan
Cyclophosphamide
Cytarabine
N-monoacetylcystine